Bookmark and Share

BioActivity Data for Compound amfenac (CID 23665728)

BioActivity Outcomes:
Active(7)
 
 
Inactive(120)
 
 
Inconclusive(8)
 
 
Unspecified(35)
 
 
Top Targets:
NR LBD AR(14)
 
 
 
NR LBD ER(14)
 
 
 
NR LBD GR(8)
 
 
NR LBD TR(6)
 
 
7tm 4(4)
 
 
 
BioAssay Types:
Confirmatory(98)
 
 
 
 
Literature(38)
 
 
 
Summary(30)
 
 
 
 
Screening(4)
 
 
 
BioActivity Types:
Potency(124)
 
 
 
 
IC50(3)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 104    Data Row: 170   Total Pages: 9   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103201400]
IC50 0.1Inhibitory activity against Prostaglandin G/H synthase [AID161308, Type: Literature]
View
2
[SID103201400]
IC50 0.2Inhibition of prostaglandin G/H synthase obtained from bovine seminal vesicles. [AID160707, Type: Literature]
View
3
[SID103201400]
IC50 0.2Evaluated for the inhibition of prostaglandin synthetase obtained from bovine seminal vesicles at the dose of 4.0 mg/kg (p.o.) [AID160886, Type: Literature]
View
4
[SID144206568]
Potency-Replicate_1 10.5909qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line [AID743079, Type: confirmatory]estrogen nuclear receptor alpha [Homo sapiens] [gi:348019627]
View
5
[SID144206568]
Ratio Potency (uM) 22.1476qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary [AID743140, Type: summary]peroxisome proliferator activated receptor gamma [Homo sapiens] [gi:216409692]
View
6
[SID144206567]
qHTS of D3 Dopamine Receptor Agonist: qHTS [AID652048, Type: screening]D(3) dopamine receptor isoform e [Homo sapiens] [gi:89191863]
View
7
[SID144206567]
qHTS of D3 Dopamine Receptor Potentiators: qHTS [AID652051, Type: screening]D(3) dopamine receptor isoform e [Homo sapiens] [gi:89191863]
View
8
[SID103201400]
Percent change of the antiinflammatory activity in the 5-h Evans Blue-Carrageenan induced pleural effusion assay at the dose of 0.8 mg/kg (p.o.) [AID170704, Type: Literature]
View
9
[SID103201400]
Oral analgesic activity was determined in mice by the acetylcholine-induced abdominal constriction assay upon ip administration of acetylcholine bromide 20 min following oral administration [AID114054, Type: Literature]
View
10
[SID103201400]
Oral analgesic activity was determined in mice by the acetylcholine-induced abdominal constriction assay upon ip administration of acetylcholine bromide 5 hours following oral administration [AID114055, Type: Literature]
View
11
[SID103201400]
Antiinflammatory activity in fasted male rat assessed as decrease in carrageenan-induced pleural fluid at 4 mg/kg, po after 5 hrs by Evans blue carrageenan pleural effusion assay relative to control [AID1130698, Type: Literature]
View
12
[SID103201400]
Antiinflammatory activity against adjuvant-induced arthritis in Lewis Wistar rat assessed as change in 11 day edema volume in adjuvant injected foot at 0.316 mg/kg, po treated once daily on days 18 to 22 and 28 to 28 [AID1130704, Type: Literature]
View
13
[SID103201400]
Toxicity in adjuvant-induced arthritis Lewis Wistar rat model assessed as change in 11 day weight at 0.316 mg/kg, po treated once daily on days 18 to 22 and 28 to 28 [AID1130682, Type: Literature]
View
14
[SID103201400]
Toxicity in adjuvant-induced arthritis Lewis Wistar rat model assessed as change in 11 day weight at 0.0031 mg/kg, po treated once daily on days 18 to 22 and 28 to 28 [AID1130686, Type: Literature]
View
15
[SID103201400]
Toxicity in adjuvant-induced arthritis Lewis Wistar rat model assessed as change in 11 day weight at 0.0316 mg/kg, po treated once daily on days 18 to 22 and 28 to 28 [AID1130687, Type: Literature]
View
16
[SID103201400]
Antiinflammatory activity against adjuvant-induced arthritis in Lewis Wistar rat assessed as potency in adjuvant injected foot treated po once daily on days 18 to 22 and 28 to 28 relative to phenylbutazone [AID1130688, Type: Literature]
View
17
[SID103201400]
Antiinflammatory activity against adjuvant-induced arthritis in Lewis Wistar rat assessed as potency in adjuvant uninjected foot treated po once daily on days 18 to 22 and 28 to 28 relative to phenylbutazone [AID1130689, Type: Literature]
View
18
[SID103201400]
Antiinflammatory activity in fasted male rat assessed as decrease in carrageenan-induced pleural fluid at 0.8 mg/kg, po after 5 hrs by Evans blue carrageenan pleural effusion assay relative to control [AID1130697, Type: Literature]
View
19
[SID103201400]
Pharmacological potency relative to indomethacin for prodrug candidate by intestinal toxicity assay. [AID212537, Type: Literature]
View
20
[SID103201400]
Antiinflammatory activity against adjuvant-induced arthritis in Lewis Wistar rat assessed as change in 11 day edema volume in adjuvant injected foot at 0.0031 mg/kg, po treated once daily on days 18 to 22 and 28 to 28 [AID1130672, Type: Literature]
View